Mahesh V. Patel bought $51k of LPCN
Chief Executive Officer at Lipocine Inc.. 25,000 shares at an average of $2.03, traded Apr 6, 2026, filed Apr 6, 2026.
Score components
- +25RoleCEO
- +7Trade size$51k at market
- +3Relative to holdingsHoldings up 18%
- +18Price context0% above the 52-week low; 83% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-015357, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 6, 2026 | POpen-market purchase Common stock | +25,000 | $2.03 | $51k | 160,679 | Apr 6, 2026 |
Related signals
Other insiders at Lipocine Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | LPCNbuy Lipocine Inc. | John W. Higuchi director | $55k 25,007 shares | +12% | |
| 41Moderate | LPCNbuy Lipocine Inc. | John W. Higuchi director | $27k 12,561 shares | +6% | |
| 61Notable | Lipocine Inc. | John W. Higuchi director | $81k 40,000 shares | +24% | |
| 64Notable | Lipocine Inc. | John W. Higuchi director | $252k 123,000 shares | +301% | |
| 64Notable | Lipocine Inc. | Mahesh V. Patel Chief Executive Officer | $51k 25,000 shares | +23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.